Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Global trends in HIV infection demonstrate an overall increase in HIV prevalence and
substantial declines in AIDS related deaths largely attributable to the survival benefits of …

Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …

Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …

Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and
bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here …

Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV,
and can prevent new infections via pre-exposure prophylaxis,,,–. However, some people …

Preexposure prophylaxis (PrEP) with a daily, oral pill containing antiretroviral drugs is highly
effective in preventing acquisition of human immunodeficiency virus (HIV) infection (1–4) …

Background Antiretroviral preexposure prophylaxis has been shown to reduce the risk of
human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting …

Objective: Preexposure prophylaxis (PrEP) offers a promising new approach to HIV
prevention. This systematic review and meta-analysis evaluated the evidence for use of oral …

Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However …